roche glp-1 drug Weighs In With Encouraging Early Clinical Data for Oral Roche commits $100M to keep
Description
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Other Ingredients: Organic Peppermint (Mentha x piperita) (leaves), OrganiPure (AgSol)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for diabetes and obesity, have shown promise in modulating reward-related brain pathways, suggesting potential benefits in the management of AUD
The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.
